In recognition of Liver Cancer Awareness Month, Liver Cancer Connect is highlighting some of the advances in prevention, screening, and treatment that are leading to increased survival among people with liver cancer. Continue reading "Fighting the Doom and Gloom: Prevention Works!"
Recent projections for the top cancer killers in 2030 confirmed some encouraging trends but also sounded a warning bell. Continue reading "It’s Time to Take On the Deadliest Cancers"
Useful confirmation of what we already thought was true. Good news…
(HealthNewsDigest.com) – DETROIT, June 9, 2014 —
Researchers have found that antiviral therapy may be successful in preventing hepatitis B virus from developing into the most common form of liver cancer, hepatocellular carcinoma (HCC).
That was the finding of a study published in the May issue of Clinical Gastroenterology and Hepatology. Investigators from Henry Ford Health System in Detroit, Geisinger Health System in Danville, Pa., and Kaiser Permanente in Honolulu, Hawaii and Portland, Ore. participated in the study, along with investigators from the Centers for Disease Control and Prevention in Atlanta.
According to the first-of-its-kind analysis of more than 2,600 adult participants with hepatitis B, those treated with antiviral therapy had a significantly lower occurrence of HCC during a five-year follow up period. Overall, 3 percent of patients developed HCC during the study’s timeframe. But patients who received antiviral therapy were 60 percent less likely to develop HCC than untreated patients.
“The results of this study allow us to reassure our patients that we are not just treating their viral levels, but that antiviral therapy may actually lessen their chance of developing liver cancer,” said the study’s lead investigator, Henry Ford Health System’s Stuart C. Gordon, M.D., who worked closely with Henry Ford Senior Scientist Mei Lu in Detroit. Continue reading here.
Liver cancer is the world’s second leading cause of cancer deaths, according to the latest World Cancer Report 2014 released by the International Agency for Research on Cancer (IARC), which is the specialized cancer agency of the World Health Organization (WHO). About 800,000 deaths per year are related to liver cancer. Continue reading "The World’s Second Deadliest Cancer Is …Preventable"
In recognition of Rare Diseases Day today, Liver Cancer Connect is honored to feature an article by guest blogger, Gail Trecosta. Gail’s son is fighting a rare form of liver cancer.
We’ve all heard or seen heartbreaking stories of children with cancer. Ours began in October 2012. Our world turned upside down when our 13-year-old son was diagnosed with fibrolamellar hepatocellular carcinoma (FHC).
Continue reading "Fighting FHC: A Family’s Battle Against a Rare Liver Cancer"
Welcome to the newly launched blog from Liver Cancer Connect, the Hepatitis B Foundation’s dedicated program on liver cancer. The blog will focus on issues that affect families facing liver cancer.
On the recent World Cancer Day 2014, we ushered in the new year with both sobering news and some optimism.
First the sobering news. The American Cancer Society recently reported1 that the number of new cases of liver cancer and the number of deaths due to this disease continue to increase.
The rate of liver/bile duct cancer has risen by 3% to 4% per year and mortality by about 2% over the past 2 decades. In sharp contrast, the death rate for all cancers combined has been steadily declining over the same period and the number of new cases has decreased for most cancers.
Liver cancer is the fifth most common cancer in the world, and the third leading cause of cancer-related deaths. In fact, every 30 seconds, one person in the world dies of liver cancer.
Yet liver cancer is largely preventable!
Eliminating the main risk factors for liver cancer — chronic hepatitis B and C infections and fatty liver disease — can stop the development of liver cancer.
Chronic hepatitis B and C infections, which cause about 85% of liver cancers worldwide, are preventable and treatable. A safe vaccine against hepatitis B (the world’s first anti-cancer vaccine) has been available since 1986. And while a cure is not yet available, hepatitis B infections can be kept under control with effective treatments. There is no vaccine yet for hepatitis C, but it can be cured. And fatty liver disease can be prevented by maintaining a healthy weight and diet.
Equally important in preventing liver cancer are screening and surveillance, which help to find the cancer early. Screening is the first test that a person undergoes to detect either an increased risk for liver cancer or the actual presence of the cancer. Surveillance refers to the regular monitoring for liver cancer on a ~6-month basis.
Early detection increases the number of treatment options available and the chances of successful treatment. A targeted oral therapy called Nexavar (sorafenib) is currently approved for liver cancer in more than 70 countries, and researchers are looking for new ways to fight liver cancer with fewer side effects. Many of these potential new treatments are being studied in clinical trials.
So there is room for optimism. With greater public awareness of the risk factors and how to prevent them, and new therapies being developed, it is possible to reverse the bleak statistics for liver cancer.
With the rallying call, “Liver cancer is preventable!” Liver Cancer Connect is putting the spotlight on the prevention of liver cancer.
Our patient-focused website (www.livercancerconnect.org) explains the main risk factors for liver cancer and the importance of screening, surveillance, and early intervention. Over the next few months we will be expanding the resources on the website and bringing you more news and information on liver cancer. We encourage you to explore the website and send us your comments.
1. Siegel R, Ma J, Zou Z, Jemal A. Cancer Statistics, 2014. CA Cancer J Clin 2014 (epub ahead of print).
Posted in Science World Report, October 17, 2013
A recent study looks at a form of hepatitis B that is only found in men and may explain higher rates for certain types of cancer.
According to a team of researchers from Seoul National University in Korea, they identified a mutation from the hepatitis B virus that seems to appear only in men and may explain why HBV-infected males are roughly five times more likely than HBV-infected women to develop certain types of liver cancer. Continue reading "Hepatitis B Mutation Seen in Only Men, Increased Risk of Liver Cancer"
Could an inexpensive test, used in conjunction with current, traditional HCC testing help reveal one’s liver cancer risk? Research for the V-chip is described in an article published in this week’s Health Canal.
Scientists from the Houston Methodist Research Institute and the University of Texas M.D. Anderson Cancer Center will receive about $2.1 million from the National Cancer Institute to learn whether a small, low-cost device can help assess a person’s risk of developing a common form of liver cancer.
The four-year project is based on technology previously developed by Houston Methodist nanomedicine faculty member Lidong Qin, Ph.D., who is the new project’s principal investigator. Qin’s “V-Chip,” or volumetric bar-chart chip, will be used to detect biomarkers for hepatocellular carcinoma (HCC), the most common cause of liver cancer. The device only requires a drop of blood from a finger prick.
The V-Chip allows the testing of up to 50 different molecules in a blood or urine sample.
“Most of the burden of HCC is borne by people who have low income, with the highest incidence rates reported in regions of the world where infection with hepatitis B virus is endemic,” Qin said. “Developing an accurate and low-cost technology that assesses the risk of cancer could make a big difference to people who ordinarily can’t afford expensive tests.”
M.D. Anderson Department of Epidemiology Chair Xifeng Wu is the project’s co-principal investigator.
Qin and Wu will see whether the V-Chip accurately detects HCC biomarkers. The researchers will also determine which combination of these biomarkers proves most predictive of disease.
Among the biomarkers the researchers will look at are antigens of hepatitis viruses B and C, aflatoxin (a fungal toxin that at high doses is associated with cancer risk), and metabolic indicators of alcohol consumption, obesity, diabetes, and iron overdose.
Tests of the V-chip will not replace traditional testing methods, but rather be carried out in tandem so that patients’ care cannot be adversely affected.
Hepatocellular carcinoma is believed to be the third-highest cause of cancer death worldwide and the ninth leading cause of cancer death in the U.S. It is most commonly caused by a past infection of hepatitis viruses B or C (HBV or HCV) and cirrhosis of the liver caused by alcohol abuse or other toxic damage.
Please visit Health News, Health Canal for more information
This weeks’ blog features one family’s experience in dealing with a rare type of cancer with the goal of bringing hope and inspiring those who may be dealing with the challenge of living with liver cancer.
In November 2005, my wife Heather and I learned something that changed our lives forever. It was the day that she was diagnosed with cancer. She had malignant pleural mesothelioma. I knew that our lives were about to change considerably, and right away I had to step into the role of caregiver for my wife. Our daughter Lily had just come in to the world three months prior, and our excitement over being new parents quickly dissolved into fear of what the future could bring. I didn’t know why we were dealt such a hand, but I knew that we had to make it through.
I started my life as a caregiver the moment that I heard Heather had cancer. We went to the doctor together that day. Sitting there, feeling trapped inside my emotions, we were faced with some difficult choices. The doctor gave us a few options for treatment nearby, like the regional hospital or university hospital, but neither of these had a program for mesothelioma. We were told about a specialist in Boston named Dr. David Sugarbaker, who was renowned for his work with mesothelioma patients. It didn’t take me any time to say, “Get us to Boston!” I knew that if my wife had any chance of surviving, she would need the best care she could possibly get.
We spent some time after that trying to get our life together. We had to make some tough decisions about child care, paying bills and work. Heather could no longer work, and I had to scale back to part time in order to be there to care for her and Lily. The worst times were being stuck at my job, thinking of my wife and the baby, and knowing that I wasn’t where I needed to be and yet I was where I had to be. I kept having these terrifying moments of doubt, where I would think of being alone and widowed with a baby to raise on my own. It was all I could do to keep it together most days.
Help came when we needed it the most through my wife’s family. Heather’s parents were extremely giving during our time of need. They provided a place for her to live after her surgery in Boston but they also provided for Lily’s child care. They even helped with medical bills. Friends were also there for us during our rough time. I will never forget the help from these people and how generous they were. It truly saved my family from desperate hardship. I will always remember that kindness.
My strongest advice to anyone in this situation is to accept every offer of help that comes your way. I learned the hard way that there is no room for pride in a battle with cancer. Even the smallest offer of help can be a huge weight off your shoulders, and at the very least will remind you that you are not alone in the fight.
Furthermore, as a caregiver you must remember to take care of yourself as well. Allow yourself to have bad days, this is inevitable and even necessary, but always remember to never, ever give up hope for a better tomorrow.
Heather would undergo intense treatment for mesothelioma over the following months, and against all odds she would eventually beat her cancer. It has been over seven years since her diagnosis, and she remains happy and healthy to this day. We hope that by sharing our story, we can help inspire others currently battling through cancer today.
Cameron Von St. James
The Hepatitis B Foundation’s Liver Cancer Webinar Series continues Wednesday, April 3rd. HBF’s first webinar was overwhelmingly successful, so we hope you’ll join us next week for “Liver Cancer and Hepatitis C: What You Need to Know”, presented by leading hepatitis C expert, Douglas LaBrecque, MD.
Dr. LaBrecque is the Professor of Medicine and Director of the Liver Service at the University of Iowa. He also served as Chief of GI and Hepatology at the Iowa City VA Hospital for 19 years. He has conducted extensive research on the development and treatment of hepatitis C, hepatitis B, and other liver diseases, including liver transplantation with more than 100 peer-reviewed manuscripts, three books, 22 book chapters and over 150 abstracts.
Liver cancer is the third leading cause of cancer-related deaths and the seventh most common cancer worldwide. But the major causes of liver cancer— such as chronic hepatitis B or hepatitis C, and cirrhosis— are largely preventable. And treatments for liver cancer are available.
Join The Hepatitis B Foundation’s webinar series to learn about the risk factors for liver cancer and the importance of liver cancer screening and surveillance. The expert presenters will describe currently available treatment options and clinical trials. These webinars are provided free of charge to help educate and raise liver cancer awareness.
Liver Cancer and Hepatitis C: What You Need to Know webinar details:
Presented by: Dr. Douglas LaBrecque
Date: Wednesday, April 3, 2013
Time: 3 pmEST; 12 pmPST
Click here to register
Download the March 6th Webinar and listen to Hepatitis B and Liver Cancer: What You Need to Know, by Dr. Robert Gish.
For additional accurate, easy-to-understand information on liver cancer, visit the Hepatitis B Foundation’s dedicated website, www.LiverCancerConnect.org.
